Pillstats
Rx only · Tablet, Extended Release · Oral

Oxcarbazepine

Oxcarbazepine

3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US9 NDCs
3 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)32624
US makers3 labelers
Packages12
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 9 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$2.84$5.67$8.51$11.35Dec 2025Apr 2026Jul 2026
$5.704
Latest avg · Jul 22, 2026
-42%
Since Dec 17, 2025
3
Active US suppliers
75%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

4.0K8.1K12K16K2025 Q12025 Q22025 Q32025 Q42026 Q1
14K
Rx · 2026 Q1
1.0M
Units dispensed
+91%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it3 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Apotex Corp.unknown6SUPPLYING
Ajanta Pharma USA Inc.unknown3SUPPLYING
Ingenus Pharmaceuticals, LLCunknown3SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.